ReviewInfectious diseases of poverty2019
Lessons from lymphatic filariasis elimination and the challenges of post-elimination surveillance in China.
Review in Infectious diseases of poverty, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- Updated annotation and meta-analysis of Brugia malayi transcriptomics data reveals consistent transcriptional profiles across time and space with some study-specific differences in adult female worm transcriptional profiles.PLoS neglected tropical diseases · 2024Pooled it
- Lymphatic filariasis in Asia: a systematic review and meta-analysis.Parasitology research · 2021Pooled it
- Gene regulation in response to host sex and infection route in Brugia pahangi with new genome annotation.G3 (Bethesda, Md.) · 2026Article
- A One Health performance evaluation system for urban parasitic disease prevention and control: The Shanghai, China pilot scheme.One health (Amsterdam, Netherlands) · 2026Article
- Diseases Caused by Parasites with Invertebrate Hosts in China: Burden and Trends of Leishmaniasis and Schistosomiasis.Pathogens (Basel, Switzerland) · 2026Article
- Bayesian hierarchical spatial ecological model assessing the nexus of vegetation index, insecticide-treated bed-nets and livestock cattle density on lymphatic filariasis transmission.BMC public health · 2025Article
- Ghana's path towards eliminating lymphatic filariasis.Tropical medicine and health · 2024Review
- Casearia tomentosa fruit extracts exposed larvicidal activity and morphological alterations in Culex quinquefasciatus and Aedes albopictus under in vitro and semi field conditions.BMC research notes · 2024Article
- Protocol for the crowdsourced image-based morbidity hotspot surveillance for neglected tropical diseases (CIMS-NTDs).PloS one · 2024Article
- Impediments to compliance during filariasis mass drug administration-Observations and recommendations to accelerate filariasis elimination in India.Frontiers in public health · 2024Article
- Programmed cell death pathways as targets for developing antifilarial drugs: Lessons from the recent findings.Journal of cellular and molecular medicine · 2023Review
- Swiss-Chinese Cooperation in Tropical Medicine: The Role of Professor Marcel Tanner.Diseases (Basel, Switzerland) · 2022Review
- Assessment on the Diagnostic Capacity for Parasitic Diseases of Health Facilities - China, 2019.China CDC weekly · 2021Article
- Evaluation of Loopamp™Frontiers in cellular and infection microbiology · 2021Article
- Advances in Vaccine Development for Human Lymphatic Filariasis.Trends in parasitology · 2020Review
- The dangers of mass drug administration of albendazole in Nepal, a Neurocysticercosis-endemic region.Tropical diseases, travel medicine and vaccines · 2020Article
- Construction and application of surveillance and response systems for parasitic diseases in China, led by NIPD-CTDR.Advances in parasitology · 2020Article
Corrections and comments
- Commented on by
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
backgroundThe Global Programme to Eliminate Lymphatic Filariasis (GPELF) was launched in response to the call proposed at the 50th World Health Assembly. The goal of the GPELF is to ensure that all the countries where the disease is endemic would have been transmission-free or would have entered post-intervention mass drug administration (MDA) surveillance by 2020. However, several countries are still not on track to discontinue MDA as planned. Thus, issues remain regarding the achievement of stated goals and how to effectively monitor the disease in the post-control and post-elimination phases. MAIN TEXT: China was once a lymphatic filariasis (LF) endemic country with heavy disease burden. There were three milestones in the LF control phase of China, including: the proposal that the major focus of the control strategy should be on infectious sources; the three regimens of diethylcarbamazine (DEC) administration according to LF endemic extent; and the establishment of the threshold for LF transmission interruption. It has been ten years since China entered the post-elimination stage (declaration of LF elimination in China was in 2007). Two schemes and a diagnostic criterion were issued to guide all levels of disease control and prevention workers that conduct LF surveillance, as well as those caring for chronic filariasis patients. Regular training courses are held to maintain LF control skills in grass-root institutions. The Notifiable Diseases Reporting System, which included LF in 2004, plays an important role in LF post-elimination surveillance. Until now, no resurgence of LF cases has been detected, except for LF residue foci being found in Fuchuan County of the Guangxi Zhuang Autonomous Region. To confirm that transmission is no longer achievable after a decade since the declaration of LF elimination in China, it is expected within the next two years a transmission assessment survey, conducted in previous LF-endemic areas.
conclusionsDEC-fortified salt can help accelerate the progress of GPELF before the sprite phase. Sophisticated diagnostic criteria, systematic surveillance regimes, the Direct Network Report system, and regular trainings can effectively prevent the recrudescence of LF during surveillance phases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.